항바이러스 병용요법 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약제 조합별, 투여 경로별, 유통 채널별, 적응증별, 지역별, 경쟁별(2020-2030년)
Antiviral Combination Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Combination, By Route of Administration, By Distribution Channel, By Indications, By Region and Competition, 2020-2030F
상품코드:1881450
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 187 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 항바이러스 병용요법 시장은 2024년에 527억 2,000만 달러로 평가되었으며, 2030년까지 CAGR 6.85%로 성장하여 784억 6,000만 달러에 달할 것으로 예측됩니다.
항바이러스 병용요법이란 바이러스 감염증의 치료에 있어 여러 가지 항바이러스제를 동시에 투여하는 치료법으로, 치료 효과의 향상, 약제 내성 발생 억제, 보다 강력한 바이러스 억제를 목표로 합니다. 시장 성장은 주로 HIV, 간염, 독감 등 바이러스 감염증의 전 세계적 확산과 다제 병용요법을 필요로 하는 약제 내성 바이러스 균주의 출현 증가에 의해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
527억 2,000만 달러
시장 규모 : 2030년
784억 6,000만 달러
CAGR : 2025-2030년
6.85%
가장 빠르게 성장하는 부문
경구
최대 시장
북미
주요 시장 촉진요인
세계 항바이러스 병용요법 시장은 전 세계적으로 바이러스 감염증의 유병률이 지속적으로 증가하고 있는 것에 큰 영향을 받고 있습니다. 다양한 바이러스 병원체의 지속적인 출현과 확산으로 인해 질병의 진행을 효과적으로 관리하고 심각한 결과를 완화하기 위해서는 고도의, 그리고 종종 여러 약물을 사용하는 치료 접근법이 필요합니다.
주요 시장 과제
새로운 병용요법 개발에 따른 높은 비용과 그에 따른 가격 책정은 세계 항바이러스 병용요법 시장의 성장에 큰 장벽으로 작용하고 있습니다. 연구개발에 필요한 막대한 자금 투자는 직접적으로 약값 상승으로 이어져 전 세계 많은 지역에서 접근 장벽을 만들어내고 있습니다.
주요 시장 동향
신약개발에 인공지능(AI)을 적용하는 것은 새로운 치료제의 발굴과 최적화를 가속화함으로써 세계 항바이러스 병용요법 시장에서 중요한 트렌드가 되고 있습니다. AI 알고리즘은 복잡한 생물학적 데이터 분석, 약물 효능 예측, 잠재적 항바이러스 화합물 스크리닝 효율화에 점점 더 많이 활용되고 있으며, 초기 개발 단계의 시간과 비용 절감에 기여하고 있습니다.
The Global Antiviral Combination Therapy Market, valued at USD 52.72 Billion in 2024, is projected to experience a CAGR of 6.85% to reach USD 78.46 Billion by 2030. Antiviral combination therapy involves the simultaneous administration of multiple antiviral drugs to treat viral infections, aiming to enhance efficacy, reduce drug resistance development, and achieve more potent viral suppression. The market's growth is primarily driven by the escalating global prevalence of viral infections such as HIV, hepatitis, and influenza, along with the increasing emergence of drug-resistant viral strains requiring multi-drug approaches.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 52.72 Billion
Market Size 2030
USD 78.46 Billion
CAGR 2025-2030
6.85%
Fastest Growing Segment
Oral
Largest Market
North America
Key Market Drivers
The Global Antiviral Combination Therapy Market is significantly influenced by the persistently rising prevalence of viral infections worldwide. The continuous emergence and spread of diverse viral pathogens necessitate advanced and often multi-drug treatment approaches to manage disease progression effectively and mitigate severe outcomes. For instance, according to the Pan American Health Organization / World Health Organization, in December 2023, the Region of the Americas alone reported over 4.2 million new cases of dengue fever, surpassing the previous record from 2019 by more than a million cases, as highlighted in their Situation Report N.1: Dengue Epidemiological Situation in the Americas. Such widespread outbreaks and increasing incidence rates across various viral diseases create an urgent and sustained demand for robust antiviral combination therapies that can address complex viral dynamics and patient needs.
Key Market Challenges
The high cost associated with developing novel combination therapies and their subsequent pricing presents a significant impediment to the growth of the Global Antiviral Combination Therapy Market. The substantial financial investment required for research and development directly translates into elevated drug prices, creating access barriers in numerous regions globally. This restricts patient access and limits the adoption of these advanced treatments, particularly in healthcare systems with budget constraints.
Key Market Trends
The application of Artificial Intelligence in drug discovery represents a significant trend in the global antiviral combination therapy market by accelerating the identification and optimization of novel therapeutic agents. AI algorithms are increasingly deployed to analyze complex biological data, predict drug efficacy, and streamline the screening of potential antiviral compounds, thereby reducing the time and cost associated with early-stage development. This technological integration is evidenced by the active engagement of international organizations, with the Council for International Organizations of Medical Sciences (CIOMS) holding meetings for its Working Group on Artificial Intelligence in Pharmacovigilance as recently as September 2025, signaling the industry's growing commitment to AI adoption across the pharmaceutical lifecycle.
Key Market Players
Celltrion Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc
AbbVie, Inc.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Cipla Limited
Viatris Inc
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Report Scope:
In this report, the Global Antiviral Combination Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Antiviral Combination Therapy Market, By Type:
Branded
Generic
Antiviral Combination Therapy Market, By Drug Combination:
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
Antiviral Combination Therapy Market, By Route of Administration:
Oral
Intravenous
Antiviral Combination Therapy Market, By Indication:
Human Immunodeficiency Virus
Hepatitis
Others
Antiviral Combination Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Antiviral Combination Therapy Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Antiviral Combination Therapy Market.
Available Customizations:
Global Antiviral Combination Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Antiviral Combination Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Branded, Generic)
5.2.2. By Drug Combination (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
5.2.3. By Route of Administration (Oral, Intravenous)
5.2.4. By Indication (Human Immunodeficiency Virus, Hepatitis, Others)
5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Antiviral Combination Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Combination
6.2.3. By Route of Administration
6.2.4. By Indication
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Antiviral Combination Therapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Combination
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Indication
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Antiviral Combination Therapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Combination
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Indication
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Antiviral Combination Therapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Combination
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Indication
6.3.3.2.5. By Distribution Channel
7. Europe Antiviral Combination Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Drug Combination
7.2.3. By Route of Administration
7.2.4. By Indication
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Antiviral Combination Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Combination
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Indication
7.3.1.2.5. By Distribution Channel
7.3.2. France Antiviral Combination Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Combination
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Indication
7.3.2.2.5. By Distribution Channel
7.3.3. United Kingdom Antiviral Combination Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Combination
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Indication
7.3.3.2.5. By Distribution Channel
7.3.4. Italy Antiviral Combination Therapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Drug Combination
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Indication
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Antiviral Combination Therapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Drug Combination
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Indication
7.3.5.2.5. By Distribution Channel
8. Asia Pacific Antiviral Combination Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Combination
8.2.3. By Route of Administration
8.2.4. By Indication
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Antiviral Combination Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Combination
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Indication
8.3.1.2.5. By Distribution Channel
8.3.2. India Antiviral Combination Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Combination
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Indication
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Antiviral Combination Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Combination
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Indication
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Antiviral Combination Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Drug Combination
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Indication
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Antiviral Combination Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Drug Combination
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Indication
8.3.5.2.5. By Distribution Channel
9. Middle East & Africa Antiviral Combination Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Combination
9.2.3. By Route of Administration
9.2.4. By Indication
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Antiviral Combination Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Combination
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Indication
9.3.1.2.5. By Distribution Channel
9.3.2. UAE Antiviral Combination Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Combination
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Indication
9.3.2.2.5. By Distribution Channel
9.3.3. South Africa Antiviral Combination Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Combination
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Indication
9.3.3.2.5. By Distribution Channel
10. South America Antiviral Combination Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Drug Combination
10.2.3. By Route of Administration
10.2.4. By Indication
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Antiviral Combination Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Drug Combination
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Indication
10.3.1.2.5. By Distribution Channel
10.3.2. Colombia Antiviral Combination Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Drug Combination
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Indication
10.3.2.2.5. By Distribution Channel
10.3.3. Argentina Antiviral Combination Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Drug Combination
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Indication
10.3.3.2.5. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Antiviral Combination Therapy Market: SWOT Analysis
